Home > Riviste > Minerva Endocrinology > Fascicoli precedenti > Articles online first > Minerva Endocrinology 2021 Oct 20

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Endocrinology 2021 Oct 20

DOI: 10.23736/S2724-6507.21.03611-3

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Association between β arrestin 2 and filamin A gene variations with medical treatment response in acromegaly patients

Ayse S. AKDEMIR 1, Derya METIN ARMAGAN 1, Ozge POLAT KORKMAZ 2, Hande M. OZKAYA 2, Pinar KADIOGLU 2, 3, Nurperi GAZIOGLU 4, Necmettin TANRIOVER 3, 5, Ahmet DIRICAN 5, Melek OZTURK 1

1 Department of Medical Biology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 2 Department of Endocrinology and Metabolism, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 3 Pituitary Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey; 4 Department of Neurosurgery, Medicine Faculty, İstinye University, Istanbul, Turkey; 5 Department of Neurosurgery, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey; 6 Department of Biostatistics, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey


PDF


BACKGROUND: Acromegaly is a disease that occurs as a result of excessive growth hormone caused by pituitary adenomas. Some acromegaly patients show resistance to somatostatin analog (SSA) treatment. Filamin-A (FLNA) and β-arrestins are thought to play a role in the response to SSAs. We aimed to investigate the relationship between FLNA-rs782079491 and β-arrestin-2-rs34230287 single-nucleotide polymorphisms and disease risk, as well as treatment response in patients with acromegaly in the Turkish population.
METHODS: The genotypes of 110 acromegaly patients and 99 controls were determined by realtime PCR. The genotype distributions were compared with clinical data on the disease.
RESULTS: There was no association between the β-arrestin-2 gene polymorphism and the response to SSA treatment in acromegaly patients. For responder patients to SSAs, the β-arrestin-2-rs34230287 CT+TT genotype was associated with higher microadenoma as compared with the CC genotype (p = 0.017). The FLNA polymorphism was not observed in the study group.
CONCLUSIONS: We showed that there was no association between the polymorphic genotypes of FLNA and β-arrestin-2 genes with acromegaly disease and SSAs response in the Turkish population. However, there was a relationship between β-arrestin-2 and some of the clinical characteristics. Furthermore, the CC genotype and the C allele are risk factors associated with tumor growth rate in acromegaly patients.


KEY WORDS: Acromegaly; β-arrestin; Filamin-A; SNP; Pituitary

inizio pagina